Peptides News and Research

RSS

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Ipsen, a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen's research is developed by Roche.

29 Apr 2010

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.

28 Apr 2010

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.

28 Apr 2010

Compugen reports revenues of $125,000 for first-quarter 2010

Compugen Ltd. today reported financial results for the first quarter ending March 31, 2010.

27 Apr 2010

Factors of hormone metabolism may make African-Americans more susceptible: Study

High blood pressure also called hypertension is a major health problem that when left untreated can lead to heart disease, stroke and kidney failure. African Americans are more likely to develop high blood pressure and develop it earlier in life than Caucasians. But the reasons for the heightened risk in African Americans still remained largely unknown, although new evidence may provide some insight.

26 Apr 2010

RXi Pharmaceuticals to present data on rxRNA therapeutic platform development at upcoming conferences

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior members of its management will be presenting at upcoming conferences and will highlight critical aspects of the development of RXi's next generation rxRNA™ therapeutic platform as well as specific preclinical data generated with this platform.

24 Apr 2010

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.

24 Apr 2010

Compugen announces development of PPI Blockers Discovery Platform

Compugen Ltd. announced today the development of its Protein-Protein Interaction Blockers (PPI Blockers) Discovery Platform, designed for the prediction of peptides to block disease associated protein-protein interactions. In a pilot validation run, predicted peptides showed positive results for drug targets in two cancer related pathways of interest to the industry.

23 Apr 2010

Potential new early cancer detection method using engineered gold nanoparticles

University of Missouri School of Medicine scientists explain a potentially new early cancer detection and treatment method using nanoparticles created at MU in an article published in the Proceedings of the National Academy of Sciences. The article illustrates how engineered gold nanoparticles tied to a cancer-specific receptor could be targeted to tumor cells to treat prostate, breast or lung cancers in humans.

23 Apr 2010

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued last month by the U.S. Food and Drug Administration (FDA) after review of the New Drug Application (NDA) submission for BYDUREON™ (exenatide for extended-release injectable suspension).

23 Apr 2010

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Mystic Pharmaceuticals today announced it has been granted U.S. Patent 7,669,597, a key technology of its VRx2™ drug delivery platform. The VRx2™ Delivery Platform provides preservative free, precision dose delivery for ophthalmic and intranasal drugs and biologics.

22 Apr 2010

Larger sized intravenous anesthetic diazepam incubated in isolation with Aβ peptide does not promote aggregation

Alzheimer's disease (AD) is a neurodegenerative disorder affecting millions of people worldwide and has become a major global concern. Uncontrolled oligomerization (aggregation) of Aβ peptide is the hallmark of AD and it is believed to be causally related to AD pathomechanism.

22 Apr 2010

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

Positive results from preclinical EP-302 program presented at AACR 2010

Drug discovery and development company Esperance Pharmaceuticals today presented positive results from their preclinical EP-302 program that support the initiation of IND enabling studies. EP-302 is a targeted membrane-disrupting peptide designed to selectively kill cells that express nucleolin on their surface. Nucleolin is a protein that is over-expressed in a wide range of cancers and tumor endothelial cells.

22 Apr 2010

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP-1 targeting, announced today that preclinical data was presented on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

21 Apr 2010

Ajinomoto AminoScience introduces new resource for peptides

Ajinomoto AminoScience, LLC announced today the launch of AjiPhase™, an evolution of liquid phase peptide synthesis containing the benefits of solid and liquid phase methodologies. This new service is designed as an innovative tool that will enable pharmaceutical companies to expand their development pipeline and provide a uniform production process through the entire development lifecycle.

21 Apr 2010

Researchers identify potential drug target for treatment of Alzheimer's disease

Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimer's disease: a receptor that is embedded in the membrane of neurons and other cells.

21 Apr 2010

ForteBio introduces new Octet QK(e) instrumentation system

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QK(e) instrumentation system. The new system, the next generation of the company's initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QK(e) system enables biosensors to be re-racked, for increased workflow flexibility and cost savings.

20 Apr 2010

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Scientists from The Scripps Research Institute have provided an answer to the 40-year-old mystery of how certain genetic mutations lead to Type 1 diabetes. This new molecular understanding could lead to novel therapies for Type 1 diabetes and other autoimmune diseases.

20 Apr 2010

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration in cardiovascular diseases, central nervous system injuries, ophthalmic indications and dermal wounds, announced today that it intends to offer units consisting of shares of its common stock and warrants to purchase shares of its common stock in a public offering.

17 Apr 2010

Peptides News and Research

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Compugen reports revenues of $125,000 for first-quarter 2010

Factors of hormone metabolism may make African-Americans more susceptible: Study

RXi Pharmaceuticals to present data on rxRNA therapeutic platform development at upcoming conferences

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

Compugen announces development of PPI Blockers Discovery Platform

Potential new early cancer detection method using engineered gold nanoparticles

Amylin, Eli Lilly and Alkermes reply to FDA complete response letter for BYDUREON NDA

Mystic Pharmaceuticals granted U.S. patent covering VRx2 drug delivery platform technology

Larger sized intravenous anesthetic diazepam incubated in isolation with Aβ peptide does not promote aggregation

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Positive results from preclinical EP-302 program presented at AACR 2010

Preclinical data of ANG1005 and ANG1007 for treatment of brain cancer presented at AACR 2010

Ajinomoto AminoScience introduces new resource for peptides

Researchers identify potential drug target for treatment of Alzheimer's disease

ForteBio introduces new Octet QK(e) instrumentation system

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

RegeneRx Biopharmaceuticals proposes common stock public offering

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News